The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
LDN Social Media
Get connected with us on social networks
Lauren - 1st May 2019 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Lauren is from the UK, and uses low dose naltrexone (LDN) for chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), fibromyalgia, and Ehlers-Danlos syndromes (EDS).
Naltrexone is a primary mu receptor antagonist and may also have an effect on delta and kappa receptors. The recommended dose for treatment of opiate and alcohol addiction is between 50 and 100 mg per day. It is available as naltrexone hydrochloride, a 50 mg tablet and is administered on a daily basis.
Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.